References
- Lu M, Chen S, Zhou Q, Wang L, Peng T, Wang G. Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1). Medicine (Baltimore). 2019;98(28):e16426. doi:https://doi.org/10.1097/MD.0000000000016426.
- Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-guérin. Eur Urol. 2016;69(1):60–69. doi:https://doi.org/10.1016/j.eururo.2015.06.045.
- Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–2203. doi:https://doi.org/10.1016/j.juro.2009.07.016.
- van der Heijden AG, Mengual L, Lozano JJ, et al. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016;64:127–136. doi:https://doi.org/10.1016/j.ejca.2016.06.003.
- Kim WJ, Kim EJ, Kim SK, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3. doi:https://doi.org/10.1186/1476-4598-9-3.
- Kang HW, Kim W-J, Yun SJ. The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma. Transl Cancer Res. 2020;9(10):6609–6623. doi:https://doi.org/10.21037/tcr-20-1243.
- van Kessel KEM, van der Keur KA, Dyrskjot L, et al. Molecular markers increase precision of the european association of urology non-muscle-invasive bladder cancer progression risk groups. Clin Cancer Res. 2018;24(7):1586–1593. doi:https://doi.org/10.1158/1078-0432.CCR-17-2719.
- Pi J, Xiong Y, Liu C, et al. A nomogram model to predict recurrence of non-muscle invasive bladder urothelial carcinoma after resection based on clinical parameters and immunohistochemical markers. J. Invest. Surg. 2021:1–9. doi:https://doi.org/10.1080/08941939.2021.2017080.
- Akgul M, MacLennan GT, Cheng L. The applicability and utility of immunohistochemical biomarkers in bladder pathology. Hum Pathol. 2020;98:32–55. doi:https://doi.org/10.1016/j.humpath.2020.01.004.